Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 1.00 |
| ▸ | CA6 | P23280 | 5/20 | 1.00 |
| ▸ | CA7 | P43166 | 5/20 | 1.00 |
| ▸ | CA9 | Q16790 | 5/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | CA4 | P22748 | 4/20 | 1.00 |
| ▸ | CA5A | P35218 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | CA3 | P07451 | 3/20 | 1.00 |
| ▸ | F13A1 | P00488 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165201 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL8073115 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL288987 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3175232 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL431884 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL288605 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL15618 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL6253721 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL4861043 | 0.97 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL573651 | 0.97 | LMNA (1.00) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477641-B1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION FOR TREATING THROMBOTIC DISORDERS | UNIV DUKE (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11617779-B2 | Inhibition of endosomal toll-like receptor activation | DUKE UNIVERSITY (US) | 2023-04-04 | — | — | US | disclosed |
| US-20170095503-A1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION | DUKE UNIVERSITY (US) | 2017-04-06 | — | — | US | disclosed |
| CN-102426187-A | Graphene matrix and application thereof in matrix-assisted laser desorption ionization time-of-flight mass spectrometry detection | JINSHENG CHENG | 2012-04-25 | — | — | CN | disclosed |
| WO-2006134224-A1 | CONTROLLING THE REGIO- AND STEREOSPECIFICITY OF ENZYME CATALYSIS WITH GUIDE MOLECULES | KEINAENEN TUOMO (FI) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006056663-A1 | METHOD OF SCREENING COMPOUNDS FOR THE TREATMENT OF DIABETES | LAAKSO MARKKU (FI) | 2006-06-01 | — | — | WO | disclosed |
| WO-2000034226-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 2000-06-15 | — | — | WO | disclosed |
| EP-1003715-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999054283-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 1999-10-28 | — | — | WO | disclosed |
| EP-0876327-A2 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 1998-11-11 | — | — | EP | disclosed |
| EP-0862425-A1 | DFMO FOR THE TREATMENT OR PREVENTION OF CERVICAL INTRAEPITHELIAL NEOPLASIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1998017623-A2 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1998013039-A1 | DFMO FOR THE TREATMENT OR PREVENTION OF CERVICAL INTRAEPITHELIAL NEOPLASIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-04-02 | — | — | WO | disclosed |
| EP-0748217-A1 | COMPOSITIONS COMPRISING A MAST CELL DEGRANULATION-BLOCKING AGENT FOR TREATMENT OF ENDOGENOUS, PAINFUL GASTROINTESTINAL CONDITIONS OF NON-INFLAMMATORY, NON-ULCERATIVE ORIGIN | KOS PHARMACEUTICALS, INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995021611-A2 | COMPOSITIONS COMPRISING A MAST CELL DEGRANULATION-BLOCKING AGENT FOR TREATMENT OF ENDOGENOUS, PAINFUL GASTROINTESTINAL CONDITIONS OF NON-INFLAMMATORY, NON-ULCERATIVE ORIGIN | KOS PHARMACEUTICALS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0618796-A1 | ALLEVIATING OR PREVENTION OF MIGRAINE HEADACHE ONSET WITH MAST CELL DEGRANULATION BLOCKING AGENTS | KOS PHARMACEUTICALS, INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993012773-A1 | ALLEVIATING OR PREVENTION OF MIGRAINE HEADACHE ONSET WITH MAST CELL DEGRANULATION BLOCKING AGENTS | KOS PHARMACEUTICALS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5002879-A | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor | MERRELL DOW PHARMACEUTICALS (US) | 1991-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095503-A1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION | TLR3, TLR9, TLR1 | CA12 4552/4885CA6 3838/4885CA7 4331/4885 |
| US-11617779-B2 | Inhibition of endosomal toll-like receptor activation | TLR3, TLR9, TLR1 | CA12 4552/4885CA6 3838/4885CA7 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.